J&J steps up alongside AbbVie to partner with fast-growing Morphic on its small molecule approach to integrins
The last six months have marked an important turning point for Morphic, a startup biotech working with new technology out of the lab of Harvard’s Tim Springer.
An $80 million B round in the fall of 2018 topped up the cash reserves, with a $100 million upfront from AbbVie coming weeks later, offering some big pharma validation and a better runway on the financials. And this morning another piece of the startup puzzle fell into place as J&J stepped in with an early discovery deal and collaborative plans as Morphic mapped out the full range of its exploration plan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
